NASDAQ:OMIC • US82933R3084
The current stock price of OMIC is 20.01 USD. In the past month the price increased by 0.6%. In the past year, price increased by 21.27%.
ChartMill assigns a technical rating of 6 / 10 to OMIC. When comparing the yearly performance of all stocks, OMIC is one of the better performing stocks in the market, outperforming 75.64% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to OMIC. OMIC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months OMIC reported a non-GAAP Earnings per Share(EPS) of -35.09. The EPS increased by 8.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.27% | ||
| ROE | -70.04% | ||
| Debt/Equity | 0.04 |
8 analysts have analysed OMIC and the average price target is 12.7 USD. This implies a price decrease of -36.54% is expected in the next year compared to the current price of 20.01.
For the next year, analysts expect an EPS growth of 11.81% and a revenue growth 9.93% for OMIC
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.99 | 195.786B | ||
| DHR | DANAHER CORP | 24.8 | 148.901B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 142.76 | 47.434B | ||
| A | AGILENT TECHNOLOGIES INC | 18.2 | 34.215B | ||
| IQV | IQVIA HOLDINGS INC | 13.67 | 30.326B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.56 | 27.785B | ||
| ILMN | ILLUMINA INC | 25.97 | 20.545B | ||
| WAT | WATERS CORP | 22.08 | 19.013B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 32.4 | 18.297B | ||
| MEDP | MEDPACE HOLDINGS INC | 26.87 | 12.594B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Singular Genomics Systems Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in San Diego, California and currently employs 255 full-time employees. The company went IPO on 2021-05-27. Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The firm has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The firm is also engaged in developing PX, which is a development-stage multiomics platform.
SINGULAR GENOMICS SYSTEMS IN
3010 Science Park Road
San Diego CALIFORNIA US
CEO: Andrew Spaventa
Employees: 255
Phone: 18583337830
Singular Genomics Systems Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in San Diego, California and currently employs 255 full-time employees. The company went IPO on 2021-05-27. Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The firm has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The firm is also engaged in developing PX, which is a development-stage multiomics platform.
The current stock price of OMIC is 20.01 USD. The price increased by 0.25% in the last trading session.
OMIC does not pay a dividend.
OMIC has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
OMIC stock is listed on the Nasdaq exchange.
8 analysts have analysed OMIC and the average price target is 12.7 USD. This implies a price decrease of -36.54% is expected in the next year compared to the current price of 20.01.
SINGULAR GENOMICS SYSTEMS IN (OMIC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-35.09).